Abstract Human immunodeficiency virus
Introduction
Human immunodeficiency virus (HIV) remains a global health problem of unprecedented dimensions. Globally, there are an estimated 33 million people living with HIV (UNAIDS 2008) . The continuing HIV epidemic highlights the urgent need for additional effective methods of prevention. Major efforts have been focused on developing vaccines, but the high genetic variability of HIV makes this approach very difficult, and protection remains elusive (Cohen 2009 ). While condoms are highly effective at preventing HIV transmission, they are a contraceptive requiring partner consent and consequently are not an available option for many women at risk of HIV infection (Shattock and Solomon 2004) . Thus, new prevention approaches that can be initiated (controlled) by women are desperately needed. One solution is the development of topical microbicides that can be applied vaginally (and possibly rectally) to prevent HIV transmission (Grant et al. 2008) . A broad range of compounds, including specific entry inhibitors of viral envelope or cellular receptors, are currently in development as microbicide candidates (Balzarini and Van Damme 2007) . Cyanovirin-N (CVN), an entry inhibitor of HIV that was initially isolated from the cyanobacterium Nostoc ellipsosporum , represents a new generation of microbicides due to its specific and potent activity, different mechanism of action, and unusual chemicophysical stability. In vivo studies with CVN formulated as a gel have shown promising efficacy as a microbicide candidate. In addition, a recent ex vivo test showed that the antiviral effect of CVN is stronger than that of PRO 2000 (Fischetti et al. 2009; Huskens et al. 2009 ), a nonspecific polyanion microbicide. The greater activity and specificity of CVN may provide a more effective next generation approach to microbicide development. In addition to properly evaluating its pharmacological action, another formidable challenge for the development of CVN is how to produce biologically active recombinant CVN (rCVN) on a large scale with relatively low cost necessary to satisfy medical use. In this review, we summarize the general knowledge as well as the potential application of CVN and then focus on the advances in large-scale production.
Structural characteristics of CVN CVN has a unique sequence of 101 amino acid residues . Although the two halves (residues 1-50 and 51-101) in CVN share a high degree of sequence homology, CVN has an extremely low sequence homology with any other known protein. It has no homology greater than eight contiguous amino acids or 20% of the total sequence to any other known protein. In addition, this protein contains four cysteines that form two intramolecular disulfide bonds. Disruption of these disulfide bonds results in the loss of CVN's anti-HIV activity (Bewley et al. 1998; Yang et al. 1999) . The disulfide bonds and lack of sequence homology make the artificial production of this protein very difficult.
At this point in time, the structure of CVN and its mutants have been solved a total of 23 times using crystallography or NMR (Protein Data Bank, http://www.rcsb.org/pdb/home/ home.do). The protein displays an internal twofold pseudosymmetry, and the two repeat sequences do not form separate domains (Bewley et al. 1998) . Wild-type (WT) CVN is a monomer in solution and exhibits a domainswapped dimer in crystal form ( Fig. 1a ; Barrientos et al. 2002) . The monomer is comprised of two independent carbohydrate-binding sites that individually bind to di-and tri-mannoses (Fig. 1b) of the gp120 protein of HIV-1 with an affinity that is stronger than that of the broadly neutralizing anti-HIV-1 antibody 2G12, another gp120-targeting entry inhibitor . High-affinity binding through multivalent binding sites on CVN and clustered oligomannosides on gp120 is essential for CVN's antiviral activity. Mutants containing two or more binding sites are functional at low nanomolar concentrations. Monovalent, monomeric mutants of CVN are inactive in inhibiting viral entry and bind gp120 with greatly reduced affinity. Constructs containing a single carbohydrate-binding domain that are capable of forming domain-swapped dimers are also functional (Liu et al. 2009 ). Owing to its special sequence and three-dimensional structure, CVN is insensitive to denaturants, detergents, organic solvents, and extreme temperatures. These features strengthen its potential as a microbicide, as well as providing a simple heat precipitation process to separate it from other host proteins when it is expressed in heterologous bacteria or cells.
Production of CVN in heterologous hosts
The production of recombinant proteins in a highly purified and well-characterized form has become a major part of the Fig. 1 Crystal structures of CVN. a The domain-swapped dimer of CVN. CVN is a three-dimensional domain-swapped dimer in the crystal structures with two primary sites near the hinge region and two secondary sites on opposite ends of the dimer. The figure was extracted from PDB (http://www.rcsb.org/pdb/explore/explore.do? structureId=1L5E). b The crystal structure of rCVN complexed to a synthetic hexamannoside at 2.4-A resolution. The binding interface constitutes two stacked α(1-2)-linked mannose rings for hexamannoside with the rest of the saccharide molecules pointing towards the solution. The figure was extracted from PDB (http://www.rcsb.org/ pdb/explore/explore.do?structureId=3GXY) pharmaceutical biotechnologists job (Terpe 2006) . As a promising microbicide candidate, a 5-mg dose of CVN, which proved to be effective in macaque studies, requires a production capacity of 5,000 kg a year to supply twice weekly doses for just 10 million women (Shattock and Moore 2003) . This scale of protein production may be achievable only by an expression system that could produce rCVN with high efficiency and low cost.
Expression of rCVN in Escherichia coli and other commensal bacteria E. coli is the most widely used organisms for r-protein production because of its profound genetic and physiological characterization, its short generation time, the ease of handling, the established fermentation know-how, and finally its high specific productivity. As a monomeric protein with two essential disulfide bonds and no glycosylation, the initial heterologous expression of CVN was performed in the periplasmic space of E. coli. Boyd et al. synthesized a sequence coding for the FLAG-CVN fusion, and succeeded in expressing it in E. coli. However, the product was a mixture of a series CVN derivatives, including intact protein, truncated protein, and ompA fused proteins that decreased its anti-HIV potency and purity. Substitution of the ompA signal peptide with the pelB sequence resulted in intact rCVN, but this expression system yielded only 10-mg target protein per liter of culture ). In addition, the purification process based on HPLC could not meet the requirement of activity determination and other large-scale operations. The low yield of CVN from the periplasmic space is due to its special sequence and membrane structure, the low chaperone and foldase level, and the high periplasmatic protease concentration in the host cell. The secretion systems of E. coli result in comparably low product yields, making them only suitable for compounds marketed in small quantities, like orphan drugs.
To increase the yield of CVN, inclusion body (IB) expression in the cytoplasm of E. coli was attempted (Colleluori et al. 2005) . Following refolding by a conventional process and purification by ion exchange chromatography, about 40 mg/L of rCVN was produced in shaking flask culture and 140 mg/40 g wet cell/L for fed-batch high cell density culture. This is the highest yield of rCVN reported to date. Unfortunately, the final product is a mixture of full-length monomeric and dimeric rCVN native proteins, and one or four N-terminal residues deleted isomers. The heterogeneity of rCVN from IB exposes the weakness of this type of expression. Several vectors to express CVN directly in E. coli were also tried, but the low yield and IB formation were disappointing. Finally, we turned our attention to the chaperon-fused expression system. Fortunately, this system with hexahistidine and small ubiquitin-related modifier (SUMO) double-tagged CVN leads to a soluble fusion protein in the cytoplasm of E. coli at a level of >30% of the total soluble protein (TSP). With this construct, intact and native rCVN can be rapidly purified in a soluble and biologically active form by two rounds of affinity chromatography with one round of SUMO protease digestion in between (Gao et al. 2010) . In a 30-L bioreactor using conventional fed-batch culture (FBC), more than 100-mg/L native rCVN was afforded (unpublished data). An N-terminal extended CVN derivative was also constructed and expressed using the same strategy. This CVN derivative displayed higher activity on cell viability and in a cell-to-cell fusion assay, as well as lower cytotoxicity. Furthermore, the yield of this CVN derivative under the same FBC conditions was approximately 170 ± 10 mg/L (unpublished data). The higher yield of this CVN derivative did not result from higher expression in the cytoplasm of E. coli, but is due to the extended sequence on the N-terminal of CVN acting as a bridge between the SUMO and CVN, and thus facilitates the digestion by SUMO protease. Overexpression of soluble SUMO-CVN in the cytoplasm of E. coli to obtain intact, homogeneous, and monomeric rCVN by simple downstream processes makes this system promising for practical applications.
CVN was also expressed in commensal Streptococcus gordonii either as excreted protein or attached to the bacterial cell surface. As an excreted protein, it was able to bind HIV-1 and when it was bound to the bacterium, it was able to capture HIV-1 (Giomarelli et al. 2002) . Another work has demonstrated the utility of Lactobacillus jensenii as agents of mucosal drug delivery to secrete CVN. This recombinant lactobacillus bacterium has been shown to produce high levels of structurally intact r-protein, exhibiting potent antiviral activity against laboratory and primary HIV-1 isolates. For example, the 50% inhibitory concentration of this lactobacillus-derived CVN to CCR5-tropic HIV BaL is only 0.3 nM (Liu et al. 2006) . The development of a novel, live microbicide that employs commensal bacteria to deliver CVN to the vaginal channel is another fascinating application of CVN (Ndesendo et al. 2008 ).
In eukaryotic host
Pichia pastoris is an alternative host that, like E. coli, can be grown cheaply and rapidly, possesses certain posttranslational modification pathways, is able to secrete more efficiently, and permits the production of r-proteins without intense process development. Introduction of the coding sequence for CVNs into P. pastoris demonstrates the potential for expression of rCVN in a eukaryotic system. Unfortunately, it is difficult to obtain native rCVN with this system because of high mannose N-glycosylation at position N30 and P51 mediated dimerization of the final product in the hinge region, both of which result in a loss of antiviral activity of rCVN . Furthermore, the yield in P. pastoris was only 10 mg/L, which is very low compared with cytoplasmic expression in E. coli.
A more feasible eukaryotic system to express CVN is a transgenic plant. The yield is approximately 130 μg/g from fresh leaves of the total plant and 0.635±0.298 mg/L in a 24-day-cultured rhizosecretion system. A bioactivity assay proved that the tobacco-synthesized CVN is almost all in the monomeric form (Sexton et al. 2006) . Under optimized conditions, the yield of the rhizosecretion culture of CVN is 3.2 mg/L, or 766 μg/g root dry weight/24 h. This is the highest reported yield for rhizosecretion of a heterologous protein. Nonetheless, for commercial viability, extensive optimization should still be undertaken to further increase the yield of rCVN in this transgenic system (Colgan et al. 2010; Drake et al. 2009 ). After the successful expression rCVN in a transgenic plant, a fusion protein of CVN and HIV-neutralizing mAb b12 was also produced in this transgenic plant. It was demonstrated that each moiety of the fusion protein retained its binding ability to gp120, and that this fusion protein exhibited increased anti-HIV potency compared to b12 or CVN alone ). Thus, production of rCVN from a transgenic plant may be a new approach for the microbicide manufacturing, although the undeveloped downstream processes, potential posttranslational modifications, and the higher cost and lower yield compared to that of E. coli make it nonviable now for meeting the emergency of the HIV epidemic.
In conclusion, CVN, a promising microbicide candidate with a special primary structure that is sensitive to disulfide bond formation and side chain modification, has been expressed in E. coli, yeast, and a transgenic plant ( Table 1) . The transgenic plant system is the most sophisticated and Ex-secreted expression of C-terminal pentahistidine fused CVN. N-glycosylated into an inactive form and conformational heterogeneity for WT rCVN, but CVN P51G mutant exhibited comparable activity and stability
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Nicotine abacus
Transgenic tobacco expression
Only detected by WB analysis. Yield in plant-130 ng/mg from the fresh leaf, 0.85% of TSP. Yield for rhizosecretion-0.635± 0.298 μg/mL after 24 days of culture Soluble expression, the yield is higher than reported IgGs in transgenic tobacco. Almost monomeric form. Tobacco contains a high content of toxic alkaloids. Restricted by downstream process and New Drug Application (NDA) regulation for the transgenic plant produced rCVN Sexton et al. (2006) RP-HPLC reverse phase-high performance liquid chromatography, VLC vacuum liquid chromatography, AC affinity chromatography, IEC ion exchange chromatography, FB fed-batch, HCDC high cell density culture, SUMO small ubiquitin-related modifier, WB western blot represents the future of production of this drug candidate. At this moment though, the soluble expression in the cytoplasm of E. coli might be the only feasible option.
Antiviral activity and a preclinical study of CVN as a microbicide
Antiviral activities and drug targets of CVN CVN was initially isolated as part of a screening program searching for naturally occurring virucidal agents that could be developed into anti-HIV microbicides. It irreversibly inactivates a broad range of immunodeficiency viruses such as T-tropic, M-tropic and dual tropic primary clinical isolates of HIV, many T-tropic laboratory strains of HIV-1, HIV-2, simian immunodeficiency virus, and feline immunodeficiency virus . As a potent virucidal protein, CVN is effective against most HIV strains with an EC 50 of less than 1 nM and a CC 50 greater than 400 nM ( Table 2 ).
The antiviral activity of CVN includes direct virucidal efficacy, inhibition of cell-to-cell fusion, virus-to-cell fusion, and cell-to-cell transmission. Preventing of the fusion and transmission of HIV-1 between infected and uninfected cells might greatly contribute to the potency of CVN against HIV (Dey et al. 2000) . The potent HIV inactivation ability of CVN makes this protein of particular interest in the development of a microbicide that would be the first line of defense in preventing the sexual transmission of HIV. Since the entry inhibitor Enfuvirtide (T-20) has been approved by the Food and Drug Administration and shown to constitute an important category of anti-HIV drugs, CVN, a potent fusion inhibitor, also might be developed into a therapeutic compound against HIV-1 if its potential mitogenicity and immunogenicity were attenuated or eliminated by means of PEGylation or other modification (Zappe et al. 2008 EC 50 50% effective concentration, CC 50 50% cytotoxic concentration, TI treatment index raising the possibility that HIV-infected cells could be targeted with these chimeric molecules ).
The carbohydrate moiety of gp120 consists of 24 Nlinked oligosaccharides, among which 11 are believed to be high mannose or hybrid type, and 13 are complex type. CVN exerts its activity by binding to high mannose oligosaccharides, located predominantly in the C2-C4 region of gp120, and prevents the virus entry by blocking fusion with the cell membrane and cell-to-cell transmission (Hu et al. 2007; Shenoy et al. 2001) . The 1.35-A high-resolution structure of P51G-m4-CVN suggests that the Arg-76 and Glu-41 residues of CVN are critical components for the high mannose specificity and affinity. Upon binding to gp120, Arg-76 undergoes a large conformational change, bringing its side chain from an unlocked position to a locked position, in which two direct hydrogen bonds to the ligand are formed. Glu-41 may contribute to the tight binding of the sugar and possibly in the selectivity for Manα(1-2)Manα (Fromme et al. 2008) . Recently, molecular dynamics simulations in solution demonstrated no conformational preferences for Arg-76. Instead, there is a very stable eight hydrogen bond network between the di-mannose ligand in gp120 and the predominant main chain atoms in CVN (Vorontsov and Miyashita 2009) . Thus, the mutual interaction between CVN and gp120 might contribute simultaneously to their high affinity and specificity. This mechanism provides guidance for the microbicide development of CVN, as well as for the design of CVN derivatives with enhanced antiviral activity.
In addition to immunodeficiency viruses, CVN is also effective against Ebola virus, influenza A and B, hepatitis C virus, measles virus, herpes simplex virus type-1 (HSV-1), and HSV-6 (Balzarini 2007; Buffa et al. 2009; Helle et al. 2006; O'Keefe et al. 2003) . The mutual feature of the viruses that are sensitive to CVN is that of N-linked high mannose oligosaccharides on the surface glycoprotein, which constitute the unique binding sites for CVN (Barrientos et al. 2006) . In a similar fashion to its effect on HIV, CVN not only blocks the entry of HSV-1 to target cells, but is also capable of significantly inhibiting membrane fusion mediated by HSV glycoproteins (Tiwari et al. 2009 ). The potent inhibitory activity of CVN against HSV-1 and other viruses suggests that this protein can be used not only for a topical microbicide against HIV-1, but also for the development of a broad spectrum antiviral reagent for other enveloped viruses.
Preclinical test of CVN against HIV
In vivo studies with CVN formulated as a gel have shown promising protection against male or female macaques (Macaca fascicularis) rectally or vaginally challenged with the highly pathogenic SHIV89.6P virus. Furthermore, CVN produced no cytotoxicity or clinical adverse effects in neither the in vitro nor in vivo model (Tsai et al. 2004; Tsai et al. 2003) . Because the efficacy of topical microbicides might be weakened by the dilution or neutralization of the vaginal fluid, semen, and personal sanitation habits or interfered by the commensal bacteria, in vitro and ex vivo models of female genital tissue explants were established to evaluate these impacts ). It was demonstrated that the potent activity of CVN remained in low nanomolar range in the presence of whole semen and was minimally impacted by the presence of Candida albicans. Furthermore, CVN potently inhibited infection of ectocervical explants and virus dissemination by tissueemigrating cells.
In another preclinical test, CVN and two other microbicide candidates currently in clinical trials, i.e., PRO 2000 and PMPA gel (tenofovir), were evaluated in a novel penile tissue explant model (Fischetti et al. 2009 ). It was found that CVN conferred 95% protection against HIV-1 at 11 μg/mL, which is similar to that seen in cervical explants and is a dose 1/500 of that shown to be protective in macaques. As a control, the dose for PRO 2000 to confer total protection was 10 times greater than that of CVN, and for PMPA, the dose was almost 100 times higher. The ability to block HIV-1 transfer by migratory cells is in agreement with the ability of CVN to weaken dendritic cellspecific HIV-1 transmission in vitro. CVN was not toxic for male or female genital tissue explants, but a degree of cytokine upregulation following 2 h exposure to CVN was observed. Together, these studies suggest that CVN is a good candidate for further testing in nonhuman primates followed by human clinical trials, although the potential mitogenic properties of CVN raise some concern about its safety.
Comparison between CVN and other lectin-based candidates
In addition to CVN, several lectins also exhibit significant activity against HIV and other enveloped viruses. So far, the most promising lectin-based anti-HIV candidates are CVN, scytovirin (SVN), Microcystis viridis lectin (MVL), and griffithsin (GRFT), all of which are found in algae. CVN and SVN take only nanomoles to inhibit half of the HIV virus in vitro and the inhibitory activity of GRFT is even stronger, with an EC 50 2/5 of that of CVN. GRFT possesses no measurable lymphoproliferation activity and is probably a safer candidate. However, the chemical and physical stability of GRFT is not as well as that of CVN, and its antiviral effect and safety remains to be evaluated in transmission animal models. Different from most of other candidates, CVN binds strongly with glycoproteins having Man8 or Man9, regardless of the number of glycans on a glycoprotein, accounting for its strong antiviral activity. Actinohivin (AH), a lectin found in a cultured actinomycete, has shown more specific affinity to gp120 because, unlike CVN, it could not bind with a single high mannose type glycan, and thus might be less toxic (Tanaka et al. 2009 ). Although CVN may cause side effects such as cytotoxicity and mitogenic activity, it has been proven effective and safe in vaginal and rectal transmission models. Large-scale production is another important issue in microbicide development and remains to be a challenge for lectins. Great advantages have been made in large-scale production of CVN with low cost, whereas efficient expression of GRFT has recently proven successful only in transgenic plant, with a yield of up to 300 mg/kg leaf (O'Keefe et al. 2009 ). Continuous advances in research provide more choices for the development of lectin microbicides, and CVN owns its advantages to be a promising candidate.
Conclusions and perspectives
Results from clinical trial on large-scale HIV prevention have been disappointing for the first generation of microbicide candidates, such as Buffergel, Carraguard, SAVVY, PRO2000, etc. (Morris and Lacey. 2010) . CVN is a promising microbicide candidate that was discovered 12 years ago and has been thoroughly tested in different assay and pharmacological models. It has displayed an impressive potential as a microbicide and could even be a targeting reagent. Using the present technology, it may be possible to produce CVN on a large scale and at low cost. The soluble cytoplasm expression of native rCVN, plus the established know-how of the bioprocesses of E. coliproduced biologics in the industrial sector, might provide a ready solution for the manufacture of this microbicide candidate. Other sophisticated approaches provide a backup for future manufacturing of the drug. Progress in structural mechanism investigation, pharmacological evaluation and heterologous production of CVN, and the breakthrough in population studies of other microbicides confer a potential on CVN. In addition, the promising progress of a HIV vaccine (Cohen 2009 ) highlighted the possibility to build a combinational program including microbicides, vaccines, and/or pre-exposure prophylaxis, as well as behavioral science interventions for more effective HIV-1 prevention.
